MENU
ACTU
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Actuate Therapeutics (ACTU) Ownership - Who owns Actuate Therapeutics?

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3)... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
175.09M
P/E Ratio
N/A
Total Cash
6.49M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
0.31
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

ACTU
Capitalization
175M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
6.49M
Total Cash/Share
0.31
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-2.65M
P/B Ratio
2000.00
Cash Flow
N/A
Earnings
-3.11
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
20
Current Ratio
0.73
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-24.66M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-567.45
Shares Held By Institutions
74.1M
Shares Outstanding - Current
20.7M
Total Liabilities
9.62M
Total Volume MTD
N/A
Value
-1
Gain YTD
6.030
View a ticker or compare two or three
ACTU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details